Venkata Budharaju, MD
Endocrinology, Diabetes & Metabolism · Pinellas Park, FLNPI 1427114735
Payments from drug & device makers
Across 224 payments — averaging $151.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Lilly USA, LLC$9K
- AbbVie$5K
- Johnson & Johnson$3K
- Novo Nordisk$679
- Abbott$383
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$27,78582%
- Travel & lodging$1,8005%
- Food & beverage$4,23813%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $14,520 |
| Lilly USA, LLC | 31 | $8,572 |
| AbbVie | 8 | $5,007 |
| Johnson & Johnson | 10 | $2,978 |
| Novo Nordisk | 57 | $679 |
| Abbott | 26 | $383 |
| Insulet Corporation | 10 | $242 |
| Dexcom, Inc. | 4 | $208 |
| Sanofi-aventis U.S. LLC | 12 | $207 |
| Amryt Pharma Holdings Ltd | 3 | $195 |
| Corcept Therapeutics | 3 | $124 |
| Ascendis Pharma Endocrinology Inc | 1 | $123 |
| Amgen | 6 | $112 |
| Lifescan, Inc. | 6 | $105 |
| Radius Health, Inc. | 2 | $60 |
| Fresenius Kabi USA, LLC | 1 | $57 |
| Senseonics, Incorporated | 2 | $36 |
| Companion Medical, Inc. | 2 | $33 |
| Bayer | 2 | $32 |
| Nevro Corp. | 1 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Merck | 2 | $27 |
| IBSA Pharma Inc. | 1 | $24 |
| Renalytix AI, Inc. | 1 | $23 |
| Valeritas, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,884 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 527 | $855,380 |
| TrulicityDulaglutide | 230 | $402,188 |
| JardianceEmpagliflozin | 314 | $391,210 |
| MounjaroTirzepatide | 260 | $363,456 |
| Tresiba Flextouch U-100Insulin Degludec | 188 | $156,521 |
| FarxigaDapagliflozin Propanediol | 121 | $128,719 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $116,670 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $65,682 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $65,365 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $54,060 |
| ProliaDenosumab | 30 | $51,922 |
| JanuviaSitagliptin Phosphate | 40 | $40,737 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $39,666 |
| SynthroidLevothyroxine Sodium | 393 | $39,597 |
| Humalog Kwikpen U-100Insulin Lispro | 118 | $38,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $679 | $937,293662 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $8,572 | $789,247550 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $17 | $463,561399 claims |
| AstraZenecaFarxiga | $14,520 | $128,719121 claims |
| MerckJanuvia, Janumet Xr | $27 | $57,23056 claims |
| AmgenProlia | $112 | $51,92230 claims |
| AbbVieSynthroid | $5,007 | $39,597393 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $7,897760 claims |
| Sanofi-aventis U.S. LLCLantus | $207 | $4,33628 claims |
| IBSA Pharma Inc.Tirosint | $24 | $4,11414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Pinellas Park
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.